Navigation Links
Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients
Date:4/1/2011

ive genotype-1 (GT-1) HCV patients were randomized (1:1:2:2) to receive either:

  • Placebo plus PegIFN/RBV;
  • BI 201335 120mg once-daily (QD) with a three-day LI of PegIFN/RBV;
  • BI 201335 240mg QD with a three-day LI of PegIFN/RBV; or
  • BI 201335 240mg QD plus PegIFN/RBV without LI

  • Patients were given BI 201335 for 24 weeks in combination with PegIFN/RBV, which was given for 24 or 48 weeks. Patients in the two BI 201335 240mg QD groups who achieved extended rapid virological response (eRVR, defined as plasma viral load less than 25 IU/ml at Week four and undetectable at Weeks 8-20), were re-randomized to discontinue PegIFN/RBV at Week 24 or continue PegIFN/RBV to Week 48.Treatment Outcomes in SILEN-C1 (Treatment-Naive Patients)Placebo
    (N=71)120mg
    QD/LI
    (N=69)240mg
    QD/LI
    (N=142)240mg
    QD
    (N=142)eRVR, %

    16

    80

    78

    87SVR, %

    56

    71

    73

    83Breakthrough*, %

    3

    6

    4

    3Relapse**, %

    14

    7

    11

    8*Rebound on treatment with BI 201335

    **Rebound after the end of all treatment Overall SVR rates reached 83 percent in the 240mg QD group (plus current SOC). A three-day lead in with SOC prior to initiation of BI 201335 was seen to reduce responses by 12 percent and 10 percent in 120mg QD/LI and 240mg QD/LI patient groups.  The LI was also associated with higher rates of viral breakthrough.  Of the patients in the 240mg QD dose group who achieved extended rapid viral response (eRVR, defined as plasma viral load less than 25 IU/ml at Week four and Weeks 8-20) and were re-randomized at Week 24, 93 percent achieved SVR with 24 weeks of SOC (PegIFN/RBV) treatment.  

    The most frequent dose-dependent adverse events (AEs) in BI 201335 treatment groups were gastrointestinal disorders, rash or photosensitivity, and jaundice resulting from isolated unconju
    '/>"/>

    SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
    2. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
    3. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
    4. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
    5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    6. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
    7. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
    8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
    9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
    10. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
    11. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/3/2015)... 2015  Dr. Cal Robinson , Psy.D., ... Center today, providing patients with new methods ... through psychological counseling and treatment programs. ... medical psychologist with an extensive career in pain ... from assessment and treatment of behavioral medicine disorders ...
    (Date:8/3/2015)... ANGELES, Aug. 3, 2015  CytRx Corporation (NASDAQ: ... in oncology, today reported financial results for the three ... overview of recent accomplishments and upcoming milestones for its ... 2015 has been very productive for CytRx. Enrollment in ... aldoxorubicin in soft tissue sarcoma (STS) continues on track ...
    (Date:8/3/2015)... FREDERICK, Md. , Aug. 3, 2015  BioElectronics ... products for pain management, announced that Andrew J. ... Taylor on his program "On Business" at 9am ... to the interview live, tune to: ... to report on the exceptional acceptance the company,s flagship ...
    Breaking Medicine Technology:Orthopaedic & Spine Center Introduces New Pain Psychologist 2CytRx Reports 2015 Second Quarter Financial Results 2CytRx Reports 2015 Second Quarter Financial Results 3CytRx Reports 2015 Second Quarter Financial Results 4CytRx Reports 2015 Second Quarter Financial Results 5CytRx Reports 2015 Second Quarter Financial Results 6CytRx Reports 2015 Second Quarter Financial Results 7CytRx Reports 2015 Second Quarter Financial Results 8CytRx Reports 2015 Second Quarter Financial Results 9CytRx Reports 2015 Second Quarter Financial Results 10CytRx Reports 2015 Second Quarter Financial Results 11CytRx Reports 2015 Second Quarter Financial Results 12CytRx Reports 2015 Second Quarter Financial Results 13CytRx Reports 2015 Second Quarter Financial Results 14UpTick News Wire Radio Show Will Interview BioElectronics' CEO Andrew Whelan 2
    ... 30 Wound Care,Innovations, LLC, a subsidiary of ... today that it will attend and exhibit at,the ... Boston. This,seminar is presented by HMP Communications, the ... and producers of the Symposium on,Advanced Wound Care. ...
    ... NIH; Findings could benefit,pregnant women worldwide, SEATTLE, ... and Human Development division of the National Institutes ... a $2.9 million grant,for a five-year research project ... known as preeclampsia and migraine., Dr. Williams ...
    Cached Medicine Technology:Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R) 2Swedish in Seattle to Study Connections Between Preeclampsia and Migraine 2Swedish in Seattle to Study Connections Between Preeclampsia and Migraine 3
    (Date:8/3/2015)... ... August 03, 2015 , ... They know every second ... St. Vincent Medical Center offers some of the best care in the nation. For ... neurointerventionalist, achieved the fastest average blood clot removal time in the country. During the ...
    (Date:8/3/2015)... , ... August 03, 2015 , ... ... to contract research organisations (CROs) for a slew of benefits, allowing them to ... and operations, boost quality with cost-effective utilisation of resources, get access to innovation ...
    (Date:8/3/2015)... CA (PRWEB) , ... August 03, 2015 , ... ... services to help patients in need. Most people know that general health emergencies, such ... Unfortunately, a fewer amount of people know where to turn to during a dental ...
    (Date:8/3/2015)... ... ... AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions ... Wednesday, August 12, 2015 at 9:45am (ET) at Le Parker Meridien in New York, ... be accessed via the investor relations section of the Company’s website. , About AxoGen, ...
    (Date:8/3/2015)... , ... August 03, 2015 , ... A July 13 ... of Stem Cells Found to Release Natural Painkiller That Can Last 'For Five Weeks'" ... According to the report, the new study showed that harvesting stem cell-rich bone marrow ...
    Breaking Medicine News(10 mins):Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 2Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 3Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3
    ... Ekahau Positioning Engine and Tags With ... Room Personnel, SARATOGA, California, July 30 Ekahau ... (RTLS), today announced,that the 12 de Octubre Hospital in ... is designed to improve security,and safety of its emergency ...
    ... 29 Microtest Laboratories has,launched a suite of ... U.S. that have yet failed to meet mandatory ... also announced,its offer of a free facility-gap-analysis audit ... level and corresponding,preparation., Pharmacies failing to comply ...
    ... Company,(NYSE: KVa/KVb), today reported that it is set ... -- principally cough/cold products -- previously,sold by ETHEX ... previously disclosed discussions with the FDA regarding the,agency,s ... by,ETHEX as well as other pharmaceutical companies for ...
    ... Challenge, SACRAMENTO, Calif., July 29 As ... Next 10 has just released,a newly updated version ... try their hand at dealing with the tradeoffs ... 2008 Budget Challenge, an online,interactive educational game, contains ...
    ... Pro Forma EPS Guidance, BETHESDA, Md., July 29 ... of $181.2 million for the,quarter ended June 30, 2008 an ... quarter. Net income increased by $2.9 million, or,57.2%, to $8.0 ... same,quarter last year., Pro forma net income applicable to ...
    ... LITTLE ROCK, Ark., July 29 Heifer International ... corporate partnership,agreement. Heifer International is a world hunger ... Greenfield, Indiana, that has,offices in 30 countries around ... improve animal health and productivity., The partnership ...
    Cached Medicine News:Health News:Madrid Hospital Improves Employee Safety With Ekahau Wi-Fi RTLS 2Health News:Madrid Hospital Improves Employee Safety With Ekahau Wi-Fi RTLS 3Health News:Microtest Offers New Services, Free Facility Audit, for Compounding Pharmacies Seeking USP 797 Compliance 2Health News:Microtest Offers New Services, Free Facility Audit, for Compounding Pharmacies Seeking USP 797 Compliance 3Health News:KV Set to Dispose of Previously Written Off Guaifenesin Inventory 2Health News:KV Set to Dispose of Previously Written Off Guaifenesin Inventory 3Health News:As Budget Stalemate Wears On - Voters Can Set Their Own Priorities 2Health News:Hanger Orthopedic Group, Inc. Beats First Call Q2 EPS Estimates by $0.05 on 13% Sales Growth and 57.2% Growth in Net Income 2Health News:Hanger Orthopedic Group, Inc. Beats First Call Q2 EPS Estimates by $0.05 on 13% Sales Growth and 57.2% Growth in Net Income 3Health News:Hanger Orthopedic Group, Inc. Beats First Call Q2 EPS Estimates by $0.05 on 13% Sales Growth and 57.2% Growth in Net Income 4Health News:Hanger Orthopedic Group, Inc. Beats First Call Q2 EPS Estimates by $0.05 on 13% Sales Growth and 57.2% Growth in Net Income 5Health News:Hanger Orthopedic Group, Inc. Beats First Call Q2 EPS Estimates by $0.05 on 13% Sales Growth and 57.2% Growth in Net Income 6Health News:Hanger Orthopedic Group, Inc. Beats First Call Q2 EPS Estimates by $0.05 on 13% Sales Growth and 57.2% Growth in Net Income 7Health News:Hanger Orthopedic Group, Inc. Beats First Call Q2 EPS Estimates by $0.05 on 13% Sales Growth and 57.2% Growth in Net Income 8Health News:Hanger Orthopedic Group, Inc. Beats First Call Q2 EPS Estimates by $0.05 on 13% Sales Growth and 57.2% Growth in Net Income 9Health News:Hanger Orthopedic Group, Inc. Beats First Call Q2 EPS Estimates by $0.05 on 13% Sales Growth and 57.2% Growth in Net Income 10Health News:Heifer and Elanco Announce Charitable Partnership 2